1. AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS. (12th June 2019) Authors: Leonard, J.; Trneny, M.; Izutsu, K.; Fowler, N.; Hong, X.; Zhang, H.; Offner, F.; Scheliga, A.; Nowakowski, G.; Pinto, A.; Re, F.; Fogliatto, L.; Scheinberg, P.; Flinn, I.; Moreira, C.; Czuczman, M.; Kalambakas, S.; Fustier, P.; Wu, C.; Gribben, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 114 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO. (12th June 2019) Authors: Gribben, J.; Trneny, M.; Izutsu, K.; Fowler, N.H.; Hong, X.; Zhang, H.; Offner, F.; Scheliga, A.; Nowakowski, G.; Pinto, A.; Re, F.; Fogliatto, L.; Scheinberg, P.; Flinn, I.; Moreira, C.; Czuczman, M.; Kalambakas, S.; Fustier, P.; Wu, C.; Leonard, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 227 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. HEALTH‐RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2) VERSUS R PLUS PLACEBO. (12th June 2019) Authors: Leonard, J.P.; Trněny, M.; Izutsu, K.; Fowler, N.H.; Hong, X.; Zhang, H.; Offner, F.; Scheliga, A.; Nowakowski, G.; Pinto, A.; Re, F.; Fogliatto, L.M.; Scheinberg, P.; Flinn, I.W.; Moreira, C.; Tabah, A.; Abouzaid, S.; Kalambakas, S.; Fustier, P.; Wu, C. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 232 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P1094: CHARACTERISTICS, MANAGEMENT, AND OUTCOMES OF PATIENTS WITH T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA AT A LARGE TERTIARY CARE CENTER. (23rd June 2022) Authors: Audil, H.; Shah, M.; Rabe, K.; Ding, W.; Hampel, P.; Bennani, N. N.; Call, T.; Hanson, C.; Wang, Y.; Koehler, A.; Schwager, S.; Leis, J.; Slager, S.; Kenderian, S.; Al-Kali, A.; Nowakowski, G.; Shi, M.; Parikh, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 984 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P1096: TREATMENT PATTERNS AND OUTCOMES IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA. (23rd June 2022) Authors: Bock, A.; Poonsombudlert, K.; Larson, M.; Gile, J.; Tawfiq, R.; Maliske, S.; Maurer, M.; Cerhan, J.; Andrade-gonzalez, X.; Saliba, A.; Paludo, J.; Inwards, D.; Ansell, S.; Witzig, T.; Habermann, T.; Link, B.; Ayyappan, S.; Nowakowski, G.; Farooq, U.; Wang, Y. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 986 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES. (23rd June 2022) Authors: Joffe, E.; Nowakowski, G.; Tun, H.; Rosenthal, A.; Lunning, M.; Ramchandren, R.; Li, C.-C.; Zhou, L.; Martinez, E.; von Roemeling, R.; Earhart, R.; McMahon, M.; Isufi, I.; Leslie, L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1011 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P1168: CHARACTERISTICS PREDICTIVE OF PROGRESSION DURING FRONTLINE TREATMENT IN AGGRESSIVE B-CELL LYMPHOMAS. (23rd June 2022) Authors: Bock, A.; Mwangi, R.; Maurer, M.; Cerhan, J.; Ng, W. L.; King, R.; Bennani, N. N.; Ansell, S.; Habermann, T.; Witzig, T.; Wang, Y.; Nowakowski, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1054 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY. (23rd June 2022) Authors: Bartlett, N. L.; Yasenchak, C. A.; Ashraf, K. K.; Harwin, W. N.; Orcutt, J.; Kuriakose, P.; Zinzani, P. L.; Mamidipalli, A.; Fenton, K.; Glenn, C.; Nowakowski, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1064 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. PB2073: LACK OF AGREEMENT ON EVENT-FREE SURVIVAL DEFINITION IN MARGINAL ZONE LYMPHOMA. (23rd June 2022) Authors: Bommier, C.; Lambert, J.; Nowakowski, G.; Zucca, E.; Thieblemont, C. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1944 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO (AUGMENT). (12th June 2019) Authors: Thieblemont, C.; Leonard, J.; Trneny, M.; Izutsu, K.; Fowler, N.; Hong, X.; Zhang, H.; Offner, F.; Scheliga, A.; Nowakowski, G.; Pinto, A.; Re, F.; Fogliatto, L.; Scheinberg, P.; Flinn, I.; Moreira, C.; Czuczman, M.; Kalambakas, S.; Fustier, P.; Wu, C. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 226 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗